NVAX Stock Price: Novavax continues to rise after rival coronavirus vaccine is halted

NASDAQ:NVAX gains 2.22% on Thursday despite broader market dip.
News of AstraZeneca halting its COVID-19 vaccine study has boosted other rivals in the industry.
Novavax has dropped nearly half of its market cap during the last month, enticing bargain investors.

Stocks Reporter FXStreet

NASDAQ:NVAX has gained where its rivals have faltered as the race for the coronavirus vaccine took a turn for the worse when AstraZeneca (NYSE:AZN) announced it was halting its final phase clinical study due to adverse effects reported in patients. Shares of Novavax jumped over 15% during the next few days as investors rushed to secure their stakes in AstraZeneca’s chief rivals. The small boost was nice for Novavax investors but the biotech stock is still down nearly 45% over the past 30 days and is down over 50% from its 52-week highs of $189.40 – although shares are still up an astounding 1500% over the last year.

Industry rivals like Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and BioNtech (NASDAQ:BNTX) all benefited from AstraZeneca’s falter, although each stock has been up and down until the end of the week. Some analysts are speaking about if a Biden Administration would hand out the same loans to these biotech companies for a coronavirus vaccine but with AstraZeneca’s failure, the desperation for a vaccine has heightened.

NVAX Stock News

Investors should act fast if they believe NVAX has a chance at taking over the lead in Operation Warp Speed. Shares have settled and Novavax also has a flu vaccine called NanoFlu that is coming down the pipe that could translate to another revenue stream moving forward. NanoFlu is getting ready to be submitted for final FDA approval which could mean that Novavax and its investors may not have to rely on a successful coronavirus vaccine for the stock to return to its previous levels.

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Stocks Reporter

FXStreet

GBP/USD loses momentum, flirts with 1.3200

GBP/USD is struggling to maintain its positive bias on Thursday, retreating toward the 1.3200 region in response to the pick in the buying interest around the Greenback. That said, Cable remains under scrutiny as cautious market sentiment keeps investors focused on the US-Iran conflict and political effervescence in the UK.

EUR/USD trims gains, challenges 1.1400

EUR/USD now gives away part of its earlier advance, receding toward the 1.1400 contention zone on Thursday. Meanwhile, the pair’s recovery comes amid extra losses in the US Dollar, at the time when while investors continue to monitor developments in the Middle East and sentiment surrounding global technology stocks.

Gold remains bid and close to $4,100

Gold accelerates its recovery and approaches the key $4,000 mark per troy ounce at the end of the week, adding to Thursday’s advance. However, expectations for a hawkish Fed remain steady and keep the yellow metal’s potential upside contained.

Crypto Today: Bitcoin at $60,000, Ethereum at $1,500, and XRP at $1 face a make-or-break test

Bitcoin (BTC), Ethereum (ETH), and Ripple (XRP) are trading in the red on Friday after three consecutive days of losses, testing their respective make-or-break support levels.

Week ahead – NFP report to challenge Dollar strength and the hawkish Fed

Dollar strength dominates markets, as the hawkish Fed overshadows geopolitics and lower oil prices. NFP week could drive September Fed hike expectations and boost market volatility. The euro lacks fresh bullish catalysts, all eyes on the preliminary inflation report and the ECB Forum.

Regime change: Inside Kevin Warsh's first move to make the Fed unreadable on purpose

The rate did not move. That was the least interesting thing about Kevin Warsh's first meeting in charge of the Fed. The FOMC held its benchmark at 3.50%-3.75% for the fourth straight meeting, exactly as priced, and then the new chair used his first press conference to dismantle the machinery the market has leaned on for a decade.